# An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

> **NCT02633293** · PHASE2,PHASE3 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 243 (actual)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease
- Combined Pulmonary Fibrosis and Emphysema

## Interventions

- **DRUG:** Inhaled Treprostinil

## Key facts

- **NCT ID:** NCT02633293
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-15
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 243 (ACTUAL)
- **Why stopped:** Inhaled treprostinil became commercially available in the US following its approval for PH-ILD
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633293, "An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02633293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*